

RESEARCH ARTICLE

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy

Nazanin Ruppender¹, Sandy Larson¹, Bryce Lakely¹, Lori Kollath¹, Lisha Brown¹, Ilsa Coleman², Roger Coleman², Holly Nguyen¹, Peter S. Nelson^{2,3}, Eva Corey¹, Linda A. Snyder⁴, Robert L. Vessella^{5,1}, Colm Morrissey¹, Hung-Ming Lam^{1*}

1 Department of Urology, University of Washington, Seattle, Washington, United States of America, **2** Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, **3** Department of Medicine, University of Washington, Seattle, Washington, United States of America, **4** Janssen Research and Development, LLC, Spring House, Pennsylvania, United States of America, **5** Department of Veterans Affairs Medical Center, Seattle, Washington, United States of America

* minglam@u.washington.edu



OPEN ACCESS

Citation: Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, et al. (2015) Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy. PLoS ONE 10(6): e0130565. doi:10.1371/journal.pone.0130565

Editor: Lucia R. Languino, Thomas Jefferson University, UNITED STATES

Received: February 11, 2015

Accepted: May 21, 2015

Published: June 19, 2015

Copyright: © 2015 Ruppender et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All gene expression files are available from the GEO database (accession number GSE64262)

Funding: This work was supported by Janssen Research and Development LLC (<http://www.janssenmd.com>), and PO1 CA85859 from the National Institutes of Health (http://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=p01).

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the disease process. In some patients, disseminated tumor cells (DTC) proliferate to form active metastases after a prolonged period of undetectable disease known as tumor dormancy. Identifying mechanisms of PCa dormancy and reactivation remain a challenge partly due to the lack of *in vitro* models. Here, we characterized *in vitro* PCa dormancy-reactivation by inducing cells from three patient-derived xenograft (PDX) lines to proliferate through tumor cell contact with each other and with bone marrow stroma. Proliferating PCa cells demonstrated tumor cell-cell contact and integrin clustering by immunofluorescence. Global gene expression analyses on proliferating cells cultured on bone marrow stroma revealed a downregulation of TGFB2 in all of the three proliferating PCa PDX lines when compared to their non-proliferating counterparts. Furthermore, constitutive activation of myosin light chain kinase (MLCK), a downstream effector of integrin-beta1 and TGF-beta2, in non-proliferating cells promoted cell proliferation. This cell proliferation was associated with an upregulation of CDK6 and a downregulation of E2F4. Taken together, our data provide the first clinically relevant *in vitro* model to support cellular adhesion and downregulation of TGFB2 as a potential mechanism by which PCa cells may escape from dormancy. Targeting the TGF-beta2-associated mechanism could provide novel opportunities to prevent lethal PCa metastasis.

Introduction

The dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the PCa disease process [1, 2]. In many cases, these disseminated tumor cells (DTC) proliferate to form active metastases after a prolonged period of undetectable disease following prostatectomy. This latency period is often referred to as tumor dormancy. To date, dormancy remains

a significant clinical challenge, as PCa patients presented with bone metastases ultimately stop responding to second line therapies and eventually succumb to the disease. Thus, it has become paramount to identify mechanisms of tumor dormancy in an effort to prevent PCa recurrence.

A dormant tumor cell does not actively proliferate, yet has the potential to multiply given the right external cues. By this definition, multiple scenarios could potentially induce dormancy, including unfavorable tumor microenvironment, nutrient starvation, the inherent nature of the DTC, or epigenetic changes caused by the microenvironment [2, 3]. However, not all instances of indolent PCa necessarily constitute dormancy. A patient may simply have slow-growing tumor cells residing at the metastatic site at the time of initial treatment and experience recurrence shortly thereafter. Others may never experience recurrence, while a subset of patients experience recurrence only after extended periods. To date, the mechanisms of dormancy remain largely unknown. However, the urokinase-like plasminogen activator (uPA) and its associated receptor (uPAR) have been implicated in the regulation of dormancy in various cancers. Specifically, high levels of uPA and uPAR induce dormancy escape by upregulating ERK/p38 ratio within cancer cells [4, 5]. This high uPAR expression was associated with the activation of $\alpha_v\beta_1$ integrin, resulting in tumor growth [4–7]. In a separate study, uPA-regulated migration of tumor cells was activated by the myosin light chain kinase (MLCK) [8] which phosphorylation was induced by ERK [9]. MLCK is a known regulator of contractility, motility, and adhesion [10, 11], however the role of MLCK in PCa dormancy escape remains unknown.

Matrix and intercellular adhesions has been implicated in tumor dormancy regulation. Studies showed that integrin-mediated cellular adhesion to the extracellular matrix activates MAPKs [12–14] which regulates tumor growth [15–19]. In PCa, upregulation of β_1 integrin promotes the growth and invasion of cells [3, 20], and interactions between tumor and stroma may be attributable to the escape of dormant cells from radiotherapy [21]. Recent studies examining human PCa cell lines on mouse bone marrow stroma have identified important factors in the mouse hematopoietic niche that regulate dormancy [22, 23].

We here characterized the dormancy and growth of three PCa patient-derived xenografts (PDXs) established from metastases obtained at rapid autopsy or surgery on human bone marrow microenvironment *in vitro*. These PDXs (LuCaP 86.2, 92, and 93) displayed *in vitro* quiescence in typical cell culture conditions which may represent dormancy and we aimed to identify the role of cell-cell adhesion in the release of PCa from dormancy in a human bone marrow context. We determined that tumor cell-cell contact on bone marrow stroma is necessary for LuCaP PDX cells to proliferate *in vitro* and was associated with a universal downregulation of TGFB2. Furthermore, LuCaP PDXs dormancy reactivation could be recapitulated by constitutively activating MLCK and cyclin-dependent kinase 6 (CDK6).

Materials and Methods

Dissociation, isolation, and culture of LuCaP PDX *in vitro*

Bone marrow stromal cells (BMSC) that were isolated from a patient with PCa bone metastases (BM2508) were seeded at 50,000 cells/cm² overnight. The following day, BM2508 cells were treated with 10 μ g/mL mitomycin C (Sigma, St Louis, MO) for 1 hour. LuCaP PDXs that were routinely passaged *in vivo* as described previously [21] were excised and dissociated using the Miltenyi human tumor dissociation kit (Miltenyi Biotec Inc., San Diego, CA; #130-95-929) and enriched by positive selection using magnetic microbeads against human epithelial antigen EpCAM/CD326 (Miltenyi Biotec Inc.; #130-061-101) according to the manufacturer's instructions. LuCaP PDX cells were then seeded on top of the BM2508 cells at either 50,000 cells/cm² (G; growing/proliferating) or 50 cells/cm² (NG; not growing/dormant). At day 8, the LuCaP

PDX cells were differentially trypsinized and enriched by positive and negative selection with magnetic beads, fluorescently labeled for EpCAM/CD326 and individually plucked with a micromanipulator as described previously [24]. Furthermore, to ensure that NG cells were dormant instead of senescent, a β -galactosidase assay (Pierce Biotechnology, Inc., Waltham, MA; #75707) was performed on all NG LuCaP PDX cells according to manufacturer's instructions. All procedures involving human subjects were approved by the Institutional Review Board of the University of Washington Medical Center and all subjects signed informed consent. The animal study was specifically approved by the University of Washington Institutional Animal Care and Use Committee and all animal procedures were performed in compliance with the NIH guidelines.

Immunofluorescent staining

The LuCaP PDX cells were dissociated, selected and plated as described above on glass coverslips conjugated with lysine. At day 8, cells were fixed with ice-cold methanol, blocked with 5% horse-goat-chicken serum and stained for EpCAM and Ki67 or α_1 integrin using a FITC-conjugated mouse monoclonal anti-human Ber-EP4 antibody (DAKO, Carpinteria, CA; F086001), and a rabbit polyclonal anti-human Ki-67 antibody (Santa Cruz Biotechnology, Dallas, TX; SC-15402) or a rabbit polyclonal anti-human ITGB1 antibody (Santa Cruz Biotechnology; SC-9970) in conjunction with a goat anti-rabbit Alexa-Fluor 546 conjugated secondary antibody (Life Technologies, Carlsbad, CA; A-11035). Coverslips were then mounted with ProLong Gold antifade reagent containing DAPI (Life Technologies; P-36931).

Cell count and WST-1 assays

C4-2B (a gift from Dr. Leland Chung; [25]) and dissociated LuCaP PDX cells (LuCaP 86.2, 92, 93, 96, 141; [26–28]) were plated in RPMI-1640 or MEM (Life Technologies) respectively supplemented with 10% fetal bovine serum (FBS). Cells were seeded either sparsely (50 cells/cm²) or densely (50,000 cells/cm²) on a confluent monolayer of BMSC (50,000 cells/cm²) that was pretreated with 10 μ g/ml mitomycin C. For C4-2B cells seeded sparsely on BMSC, after 1 and 8 days, cells were stained for EpCAM, Ki67, and DAPI as described above. Only EpCAM+ epithelial cells (representing C4-2B cells because BMSC are EpCAM-) were counted in the whole chamber under a fluorescent microscope using 200 \times magnification. For C4-2B cells seeding without BMSC, WST-1 assay (Roche Diagnostics Corporation, Indianapolis, IN) was carried out according to the manufacturer's instructions. Absorbance was read on a microplate reader at 450 nm, and the background absorbance (media only) was subtracted from all readings. For LuCaP PDX cells, after 3, 7, and 14 days on BMSC, cells were trypsinized, stained for EpCAM and Ki67 as described above, and resuspended in 50 μ l of ProLong Gold antifade reagent containing DAPI. Two-aliquots of 10 μ l of stained cells were counted and EpCAM + epithelial cells (i.e. LuCaP PDX cells) were recorded.

Flow cytometric analysis

C4-2B cells were cultured overnight in RPMI-1640 medium supplemented with 10% FBS and then treated with DMSO or ML-7 (10 μ M) for 24h and 48h. The treated cells were trypsinized, fixed, stained with 10 μ g/ μ L DAPI (4',6-diamidino-2-phenylindole, Life Technologies)/1% NP-40 /10% DMSO, and lysed using 25G syringe. At least 10,000 stained cells were analyzed using BD LSR II Flow Cytometer System (BD Biosciences, San Jose, CA) and cell cycle was analyzed by MultiCycle (De Novo Software, Glendale, CA)

Viral transduction and drug treatments of LuCaP PDX cells *in vitro*

LuCaP PDXs were dissociated and selected as described above and plated at 50,000 cells/cm² without stromal cells. The following day, cells were transduced at an MOI (multiplicity of infection) of 10 with one of the following: an adenoviral vector that either contained an activated form of myosin light chain kinase (A-tMK, a gift from Drs. Zuzana Strakova, Jody Martin, and Primal de Lanerolle, [29]), an empty vector, or a lentiviral vector that contained either cDNA for CDK6 or GFP (Applied Biological Materials, pLentiIII-EF1 α). Cells were transduced in MEM supplemented with 10% FBS and 8 μ g/mL polybrene (Santa Cruz Biotechnology). Cells were either immunofluorescently stained as described above or trypsinized for RNA extraction. To determine whether MLCK activity is necessary for PCa proliferation, C4-2B cells, which readily proliferate *in vitro*, were plated at 50,000 cells/cm² in RPMI medium (Life Technologies) supplemented with 10% FBS. The cells were then either treated with 10 μ M ML-7 (Sigma; I2764) or DMSO control for 24 hours.

RNA extraction and amplification

For 10-cell transcriptomic study, 10 individually isolated cells per xenograft line were lysed and amplified cDNA was generated from the total RNA using the NuGEN Ovation RNA Amplification System as described previously [24, 30]. The cDNA was arrayed on Agilent 44K whole human genome expression oligonucleotide microarrays (Agilent Technologies, Inc.). For other *in vitro* experiments, RNA was isolated using the RNEasy mini kit (Qiagen Inc., Valencia, CA). One microgram of RNA was reverse transcribed using the Qiagen RT² first strand kit, followed by PCR array or RT-qPCR analysis.

Labeling and hybridization of amplified material to whole human genome expression oligonucleotide microarrays

Amplified cDNA from each sample was labeled using the BioPrime Total Genomic Labeling System (Life Technologies, Grand Island, NY) and microarray was performed according to previous procedures [24, 30] with slight modifications. Briefly, hybridization probes were prepared by combining 4 μ g of Alexa Fluor 3-labeled sample with 400 ng Alexa Fluor 5-labeled reference. The probes were denatured at 95°C and hybridized at 63°C on Agilent Human 4x44K microarrays (Agilent Technologies, Inc., Santa Clara, CA), washed, and fluorescent array images were collected using the Agilent DNA microarray scanner. The data were loess normalized within arrays and quantile normalized between arrays in R using the Limma Bioconductor package. Data were filtered to remove probes with mean signal intensities below 300. The Statistical Analysis of Microarray (SAM) program (<http://www-stat.stanford.edu/~tibs/SAM/>) [31] was used to analyze expression differences between groups using unpaired, two-sample t-tests and controlled for multiple testing by estimating q-values using the false discovery rate (FDR) method. Microarray data are deposited in the Gene Expression Omnibus database under the accession number GSE64262.

Gene expression analyses

To determine whether differential transcription observed in NG (not growing/dormant) versus G (growing/proliferating) groups were enriched for genes within canonical pathways and Gene Ontology gene sets, the t-test results were subjected to Gene Set Enrichment Analysis (GSEA) using preranked mode with permutation testing of the gene sets to adjust for multiple hypothesis testing, generating an FDR. Unsupervised, hierarchical clustering of the most differentially expressed was performed between NG and G groups based on SAM score (SAM score >2 and

$p \leq 0.05$, a total of 238 genes) using Cluster 3.0 (bonsai.hgc.jp/~mdehoo/software/cluster/software.htm) and Java TreeView (<http://jtreeview.sourceforge.net/>).

Ingenuity Pathway Analysis

The 238 differentially expressed genes between NG and G groups were imported into Ingenuity Pathway Analysis (IPA, Ingenuity Systems; <https://www.ingenuity.com>) to identify molecular and cellular functions and upstream regulators involved in cell proliferation or dormancy as previously described [30].

Quantitative real-time PCR

For PCR array, 25ng of cDNA was used for human cell-cycle PCR array (Qiagen Inc., PAHS-020Z) according to manufacturer's instructions. For qPCR analysis, 2ng (G and NG 10-cell study) or 10ng (lentiviral transduction studies) of cDNA was used for the Platinum SYBR Green qPCR SuperMix-UDG system (Life Technologies, 11733–038) in conjunction with the following primers: CDK6: (F) 5'AGGCTGCTGTTTTCTCTCCA3', (R) 5'CCACACTGCTTCTTGGGTCT3'; E2F4: (F) 5'TGATGTGCCTGTTCTCAACC3', (R) 5'GAGTCCTGTTCCCTGTCT3'; RPS15: (F) 5'TCCGGCAAGATGGCAGAAGTAG3', (R) 5'CCACGCCGCGGTAGGT3'; CDC42: (F) 5'GTCACAGTTATGATTGGTGGAGA3', (R) 5'TCAGCGGTCGTAATCTGTCA3'; FN1: (F) 5'AAGAGGCAGGCTCAGCAAAT3', (R) 5'GTCATAACAACCGGCTTGC3'; TGF β 2: (F) 5'TCTTCCCCTCCGAAAATGCC3', (R) 5'TCTCCATTGCTGAGACGTCAA3'.

Results

PDX cells require cell-cell contact to proliferate *in vitro*

The PCa xenografts we have established from metastases obtained at rapid autopsy or surgery do not proliferate *in vitro* after dissociation under standard monoculture conditions [32]. Of the five LuCaP PCa PDX lines we studied, none of them displayed measurable β -galactosidase activity (data not shown), suggesting these cells are dormant rather than senescent. As dormant cells by definition retain the potential to proliferate, we sought to determine whether these xenografts could be "activated" *in vitro*. We developed an *in vitro* model recapitulating the PCa cells in contact with BMSC and allowed the LuCaP PDX cells seeded either sparsely without tumor-tumor cell contact (NG, not growing, 50 cells/cm²) or densely where cells were in direct contact with each other (G, growing, 50,000 cells/cm²; Fig 1A). We here reported that when LuCaP 86.2, 96, and 141 were seeded densely on a monolayer of BMSC, they showed an increase in cell number after 14 days, whereas the cells that were seeded sparsely failed to proliferate (Fig 1B and data not shown). In contrast, C4-2B cells seeded sparsely on BMSC showed an increase in cell number after 7 days (S1 Fig). To visually detect the association between tumor cell-cell contact and proliferation, we expanded the study to five LuCaP lines for immunofluorescent detection. After 14 days in culture, no positive Ki67 staining was detected in NG cells that were sparsely seeded without tumor cell-cell contact (Fig 1C, upper panel). Consistent with the trypan blue exclusion assay, positive Ki67 staining was observed in G cells that were densely seeded and displayed cell-cell contact, suggesting that tumor cell-cell contact was associated with cell proliferation (Fig 1C, lower panel).

β 1 Integrin activity associates with LuCaP PDX cell proliferation *in vitro*

When direct cell-cell contact occurs, integrins were reported to be activated resulting in cell cycle progression and cell proliferation [33]. We therefore examined in LuCaP PDX cells




Fig 1. LuCaP PCa PDX cells grow on a monolayer of bone marrow stromal cells (BMSC) when seeded densely. A) A scheme showing the *in vitro* culture condition for not growing (NG) and growing (G) LuCaP PDX cells on BMSC. LuCaP cells were seeded sparsely at 50 cells/cm² or densely at 50,000 cells/cm² on a confluent layer of BMSC (50,000 cells/cm²) pretreated with 10 μg/mL mitomycin C to inhibit BMSC cell division. B) LuCaP cells seeded densely on BMSC were quantified by positive EpCAM staining on day 3, 7, and 14 post-seeding. C) LuCaP cells (86.2, 92, 93, 96, and 141) were seeded sparsely (upper panel; NG) or densely (lower panel; G) on BMSC. After 14 days, cells were fixed with ice-cold methanol and fluorescently stained with Ki67 to assess proliferation. Green, EpCAM; Red, Ki67; Blue, DAPI. White arrow: sparsely seeded cells showing negative Ki67 staining after 14 days. Magnification: 200x. Scale bar: 50 μm. Experiments were repeated 2–3 times and graphs showing mean ± SEM or representative pictures were shown.

doi:10.1371/journal.pone.0130565.g001

whether β_1 integrin clustering was activated in response to cell-cell contact. In LuCaP 86.2, 92, and 93, when seeded densely on a monolayer of BMSC, the proliferating G cells showed clustering of β_1 integrin, whereas the non-proliferating NG cells seeded sparsely did not display clustering of β_1 integrin (Fig 2).

Gene expression analysis revealed downregulation of TGFB2 in proliferating cells

Next, we conducted microarray gene expression analysis to delineate the mechanisms underlying the activation of β_1 integrin and cell proliferation. A total of 238 genes (SAM score ≥ 2 or ≤ -2 , $p < 0.05$) were differentially expressed between dormant/not growing (NG) and proliferating/growing (G) cells in LuCaP 86.2, 92, and 93 (Fig 3A). We observed that cellular movement was the top molecular and cellular function altered (Fig 3B, $p < 0.05$) and a decreased activation was predicted (Fig 3C, z-score -2.4) in G when compared to NG cells. Interestingly, Ingenuity Pathway Analysis identified a top regulator effector network for those genes involved in the decreased activation on cellular movement and demonstrated that endothelin 1 (EDN1) was the common upstream regulator for the downregulation of CDC42, FN1, and FOSL1, which




Fig 2. β_1 integrin clusters were observed in LuCaP PDX cells proliferating *in vitro*. LuCaP 86.2, 92, and 93 were dissociated and cultured on a confluent monolayer of BMSC. β_1 integrin immunofluorescent staining revealed integrin clustering (red clusters and highlighted by the white arrow) in densely seeded cells that were growing (G). This clustering was not detected in sparsely seeded, nonproliferative cells (not growing, NG). Green, EpCAM; Red, β_1 integrin; Blue, DAPI. Magnification: 200x. Scale bar: 20 μ m.

doi:10.1371/journal.pone.0130565.g002




Fig 3. Genes associated with cellular movement were downregulated in proliferating LuCaP cells. A) Heat map of hierarchically clustered differential gene expression in NG and G LuCaP PDX cells. Green, downregulated; red, upregulated. B) Ingenuity pathway analysis showing cellular movement was the top molecular and cellular function altered between NG and G cells. C) List of eight genes that were involved in the decreased activation of cellular movement in G when compared to NG cells. D) EDN1 was predicted to be the top regulator that affected the cell movement via downregulation of FN1, CDC42, and FOSL1. E) Quantitative real-time PCR showed a downregulation of FN1, CDC42 and TGFB2 in growing LuCaP lines. Data were normalized to the levels of housekeeping gene RPS15. NG: not growing; G: growing.

doi:10.1371/journal.pone.0130565.g003

resulted in decreased cell movement (Fig 3C and 3D). Despite EDN1 being identified as the top common upstream regulator for decreased cellular movement in G when compared to NG cells, microarray expression analysis showed that it was not significantly altered in G when compared to NG cells (1.2 fold upregulation in G cells with a SAM score 0.2, data not shown). Since *FOSL1* has a very low endogenous level, therefore we focused on validating *CDC42* and *FN1* using real-time qPCR and found that both genes were downregulated in G cells in two of the three LuCaP PDX lines tested (Fig 3E). Furthermore, *TGFB2* is a known downstream effector of β_1 integrin and upregulation of *TGFB2* expression has been reported to be associated with migration and cancer dormancy [34, 35], we examined and found that *TGFB2* expression was consistently downregulated in G when compared to NG cells in all three LuCaP PDX lines by real-time qPCR (Fig 3E). In clinically derived DTC isolated from the bone marrow, we validated that *FN1* ($p < 0.01$, from gene expression dataset GSE48995, [26]) and *TGFB2* [35] were upregulated in patients with no evidence of disease when compared to patients with active PCa metastasis, whereas no significant gene expression change for *CDC42* ($p = 0.67$) was detected between the two groups of DTC (data not shown).

Activation of MLCK promoted PCa PDX cells proliferation via CDK6 in the absence of BMSC

Myosin light chain kinase (MLCK) is a common effector for β_1 integrin, CDC42 and TGF β 2 and its activation has been implicated in cell proliferation [36–38]. To determine if activation of MLCK is involved in LuCaP PDX cell proliferation, we virally transduced a constitutively active form of MLCK (A-tMK) in LuCaP PDX cells. A-tMK transduction in LuCaP 86.2, 92, and 93 cells that normally do not proliferate resulted in cell clustering and positive Ki-67 expression, whereas cells transduced with an empty vector did not show cell clustering or positive Ki67 staining (Fig 4A). Gene expression analysis focusing on cell cycle regulators demonstrated that A-tMK-transduced LuCaP cells expressed an upregulated level of cyclin-dependent kinase 6 (CDK6, 3 to 22 fold) and a concurrent downregulated level of E2F transcription factor 4 (E2F4, 4 to 6 fold; Fig 4B).

To validate the involvement of MLCK activation in cell proliferation, we inhibited MLCK in C4-2B cells that readily proliferate *in vitro* in an attempt to inhibit cell proliferation. Upon MLCK inhibition by the MLCK inhibitor ML-7, C4-2B cell proliferation was reduced as evidenced by the loss of Ki67 staining (Fig 4C), the decrease in WST-1 absorbance (Fig 4D), and the arrest of cells in the G1 phase (S2 Fig). In addition, the decrease in cell proliferation was accompanied by a 4.9-fold downregulation in CDK6 mRNA expression in C4-2B cells treated with ML-7 ($p = 0.007$). The expression of E2F4, however, did not show a significant upregulation in C4-2B cells (Fig 4E). Collectively, the data suggested that activation of MLCK played a role in stimulating cell proliferation which is associated with an upregulation of CDK6.

Overexpression of CDK6 facilitates the proliferation of LuCaP xenografts *in vitro*

To validate upregulation of CDK6 promoted LuCaP PDX cell proliferation, we infected LuCaP 86.2, 92, and 93 cells with lentivirus containing constitutively active CDK6 vector and examined the proliferation. LuCaP 86.2, 92, and 93 cells normally did not proliferate in the absence of BMSC, however ectopic expression of CDK6 promoted cell proliferation as evidenced by the positive Ki67 staining (Fig 5).

Discussion

PCa cells may remain quiescent/dormant for years and proliferate to form active metastases at distant sites. Little is known to date about the mechanisms underlying the induction and release from dormancy in PCa cells that reside in the bone marrow. Major reasons include the lack of patient specimens and relevant human *in vitro* and *in vivo* models. We previously reported a potential dormancy signature associated with DTC isolated from PCa patients with no evidence of disease [30]. Here, instead of using immortalized PCa cell lines that readily proliferate *in vitro*, we used clinically relevant PDX cells to examine the mechanism underlying direct cell-cell interaction to restore cell proliferation. We characterized three LuCaP PCa PDXs residing on the human bone marrow stroma, which displayed quiescent/dormant and proliferating phenotypes depending on the cell seeding density. Our results showed that tumor cell-cell contact induced cell proliferation which may represent dormancy escape via activation of β_1 integrin associated with universal downregulation of TGF β 2 signaling and upregulation of MLCK activation/CDK6 in PCa PDXs.

Recent studies in other solid tumors, such as in the head, neck, and breast, have implicated elements of the cytoskeletal migration and adhesion machinery in the activation of indolent tumor cells [4–7, 38–41]. β_1 Integrin is critical for the initiation of tumorigenesis and the




Fig 4. Constitutive activation of MLCK promotes proliferation of LuCaP PDX cells via upregulation of CDK6. A) LuCaP cells were infected with lentivirus containing A-tMK (constitutively activate MLCK) showed positive Ki67 staining, whereas cells transduced with an empty vector did not. B) In LuCaP 86.2, 92, and 93, ectopic expression of A-tMK induced an upregulation of CDK6 and a concurrent downregulation of E2F4 when compared to that of the empty vector-transduced cells. Inhibition of MLCK with the MLCK inhibitor ML-7 suppressed proliferation by C) abolishing Ki67 expression, D) decreasing cell viability assessed by WST-1 assay and E) downregulating CDK6 expression. E2F4 expression was not altered by the ML-7. Green, EpCAM; Red, Ki67; Blue, DAPI. Magnification: 200x. Scale bar: 20 μ m. ** $p < 0.01$ as compared to the DMSO control. CDK6: cyclin-dependent kinase 6; E2F4: E2F transcription factor 4.

doi:10.1371/journal.pone.0130565.g004

maintenance of the proliferative capacity of tumors [33, 41]. In PCa, we found that cell-cell contact, both between tumor cells and with an underlying stroma, was associated with the activation of β_1 integrin and was essential to facilitate the growth of quiescent PCa xenograft cells *in vitro*. While cell-cell contact has to our knowledge not been directly reported as a requirement for dormancy release, several mechanisms associated with the migration and adhesion of




Fig 5. CDK6 overexpression induced proliferation of LuCaP PDX cells *in vitro*. LuCaP 86.2, 92 and 93 cells were lentivirally transduced to overexpress CDK6 and cultured *in vitro* to assess proliferation. Positive Ki67 indicated that CDK6 overexpression facilitated proliferation in these cells. Green, EpCAM; Red, Ki67; Blue, DAPI. Magnification: 200x. Scale bar: 20 μ m.

doi:10.1371/journal.pone.0130565.g005

tumor cells have been implicated in this process. Specifically, activation of $\alpha_5\beta_1$ integrin has been shown to release human squamous carcinoma and breast cancer cells from dormancy [6, 7, 39, 41], and activation of $\alpha_5\beta_1$ integrin induce cell adhesion and migration [42, 43] as well as proliferation on extracellular matrix [44]. Thus, it is not surprising that given an opportunity to come into contact within the bone marrow microenvironment, these normally quiescent LuCaP PDX cells begin to proliferate *in vitro*.

Activation of β_1 integrin has been shown to induce the downregulation of TGF β_2 and Cdc42 [45, 46]. Global gene expression analysis on the reactivated cells versus dormant cells highlighted a decrease in TGF β_2 signaling in proliferating PCa PDX cells which was consistent with the observation that TGF β_2 induced dormancy of malignant DTC in head and neck squamous cell carcinoma [47]. This is in concordance with the data from clinically derived DTC that *TGFB2* expression is higher in PCa patients with no evidence of disease when compared to patients with advanced disease [35]. Furthermore, Cdc42 was implicated in activation of p38 and growth arrest in cancers [7] and was downregulated in proliferating PCa PDX cells in the current study. Of note, MLCK is a well-known downstream effector of adhesion- and motility-mediated mechanisms including β_1 integrin [9, 10, 38, 40], and its activation has been linked to cell survival [40]. In our study, the downregulation of CDC42 and TGFB2 pointed to a possible activation of MLCK leading to cell proliferation. Indeed, introduction of constitutively active MLCK alone was adequate to induce proliferation in LuCaP PDX cells that normally retain dormant *in vitro*. Conversely, C4-2B cells, which readily proliferate *in vitro*, were growth suppressed upon treatment with the MLCK inhibition ML-7. These data correlated well with a previous study by Barkan and colleagues that demonstrated quiescence *in vitro* and inhibition of metastatic outgrowth of various breast cancer cell lines upon inhibition of MLCK [38].

In the current study, activation of MLCK resulted in an upregulation of CDK6 in all three LuCaP PDX lines. CDK 6 associates with cyclin D1 to transition cells through the G1 phase of the cell cycle [48] and is regulated by the androgen receptor (AR) [49]. Instead of acting as a primary regulator, AR may act as an enhancer for CDK6 expression because *CDK6* upregulation upon MLCK activation was 5–7 fold higher in the AR-positive LuCaP 92 and LuCaP 86.2 cells compared to the upregulation in AR-negative neuroendocrine LuCaP 93 cells [26, 27]. On the other hand, E2F4 is known to act in conjunction with Smad3 as a cofactor for TGF transcription [50], which has been shown to induce apoptosis in PCa [51, 52]. Furthermore, E2F4 has been demonstrated to enforce G2 arrest in C4-2B cells in response to genotoxic stress [53]. We observed a downregulation of the E2F4 in proliferating LuCaP PDXs expressing activated MLCK, suggesting that the downregulation in E2F4 may be allowing LuCaP PDX cells to progress through the cell cycle and escape quiescence/dormancy (Fig 6).

Collectively, we presented the first *in vitro* model demonstrating non-proliferating PCa PDX cells resumed proliferation on human bone marrow stromal microenvironment. These models provide evidence to support that direct cell-cell interaction promotes cell proliferation partly via β_1 integrin activation. A clinically interesting but not yet addressed question is whether or not a patient showing an increased number of DTC (i.e. increased chance of DTC contact with each other) will result in an increased rate of tumor cell proliferation and hence metastatic outgrowth. Maintaining disseminated PCa cells in a dormant, indolent state is an attractive clinical prospect as is inducing active PCa cells to become dormant. However, such treatments require an intimate understanding of PCa dormancy mechanisms. While confirmatory *in vivo* studies are required to conclusively determine a dormancy release mechanism in PCa, these findings represent an important and encouraging first step in the identification of such a mechanism for this heterogeneous disease.




Fig 6. Potential mechanism for PCa release from quiescence/dormancy. Decreased fibronectin activation on β_1 integrin downregulates TGF β_2 and Cdc42 resulting in activation of MLCK. This activity leads to the deactivation of growth suppressor like E2F4 and activation of cell cycle regulator CDK6, promoting cell proliferation.

doi:10.1371/journal.pone.0130565.g006

Supporting Information

S1 Fig. C4-2B cells grow on a monolayer of bone marrow stromal cells (BMSC) when seeded sparsely. A) C4-2B cells were seeded sparsely (50 cells/cm²) on BMSC, cells were fixed with ice-cold methanol and fluorescently stained for Ki67 to assess proliferation. Green, EpCAM; Red, Ki67, Blue, DAPI. Magnification: 200x. Scale bar: 50 μ m. B) EpCAM-positive cells were counted on day 1 and day 7. Data are presented as mean \pm S.D of two independent experiments. **p<0.01 when compared to day 1. (PDF)

S2 Fig. Cell cycle analysis of ML-7 treatment on C4-2B cells. A) A representative histogram of DAPI-stained C4-2B cells treated with either DMSO or ML-7 (10 μ M) for 24h or 48h. Cell cycle was analyzed by flow cytometry. B) Percentage of cells in G1, S, and G2/M phase of C4-2B cells treated with DMSO or ML-7. Data are presented as mean \pm S.D of two independent experiments. *p<0.05 when compared to the DMSO control. (PDF)

Acknowledgments

The material is also the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington (R.L.V. is a research career scientist). H.M.L. is a recipient of the Young Investigator Award from the Prostate Cancer Foundation, the Career Development Award from the Pacific Northwest Prostate Cancer SPORE (P50 CA097186) and an Idea Development Award from the Department of Defense (W81XWH-14-1-0271). We would like to thank Dr. Julio Aguirre-Ghiso for his advice, Dr. Leland Chung for the C4-2B cells, Ms. Donna Prunkard for the flow cytometry analyses, and Drs. Zuzana Strakova, Jody Martin, and Primal de Lanerolle for the A-tMK construct.

Author Contributions

Conceived and designed the experiments: NR LAS RLV CM HML. Performed the experiments: NR SL BL LK LB IC RC. Analyzed the data: NR IC LB CM HML. Contributed reagents/materials/analysis tools: PSN EC HN LAS RLV CM HML. Wrote the paper: NR SL BL LK IC RC PSN EC LAS RLV CM HML.

References

1. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. *Clin Cancer Res* 15(2): 677–683. doi: [10.1158/1078-0432.CCR-08-1754](https://doi.org/10.1158/1078-0432.CCR-08-1754) PMID: [19147774](https://pubmed.ncbi.nlm.nih.gov/19147774/)
2. Lam HM, Vessella RL, Morrissey C (2014) The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow. *Drug Discov Today Technol* 11: 41–47. doi: [10.1016/j.ddtec.2014.02.002](https://doi.org/10.1016/j.ddtec.2014.02.002) PMID: [24847652](https://pubmed.ncbi.nlm.nih.gov/24847652/)
3. Ruppender NS, Morrissey C, Lange PH, Vessella RL (2013) Dormancy in solid tumors: implications for prostate cancer. *Cancer Metastasis Rev* 2013; 32(3–4): 501–509. doi: [10.1007/s10555-013-9445-5](https://doi.org/10.1007/s10555-013-9445-5) PMID: [23907184](https://pubmed.ncbi.nlm.nih.gov/23907184/)
4. Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. *J Cell Biol* 147(1): 89–104. PMID: [10508858](https://pubmed.ncbi.nlm.nih.gov/10508858/)
5. Allgayer H, Aguirre-Ghiso JA (2008) The urokinase receptor (u-PAR)—a link between tumor cell dormancy and minimal residual disease in bone marrow? *APMIS* 116(7–8): 602–614. doi: [10.1111/j.1600-0463.2008.01230.x](https://doi.org/10.1111/j.1600-0463.2008.01230.x) PMID: [19133014](https://pubmed.ncbi.nlm.nih.gov/19133014/)
6. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. *Mol Biol Cell* 12(4): 863–879. PMID: [11294892](https://pubmed.ncbi.nlm.nih.gov/11294892/)
7. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). *Cancer Res* 2003; 63(7): 1684–1695. PMID: [12670923](https://pubmed.ncbi.nlm.nih.gov/12670923/)
8. Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somlyo AV, et al. (1999) Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. *J Cell Biol* 146(1): 149–164. PMID: [10402467](https://pubmed.ncbi.nlm.nih.gov/10402467/)
9. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de LP, Cheresh DA. (1997) Regulation of cell motility by mitogen-activated protein kinase. *J Cell Biol* 137(2): 481–492. PMID: [9128257](https://pubmed.ncbi.nlm.nih.gov/9128257/)
10. Huang C, Jacobson K, Schaller MD. (2004) MAP kinases and cell migration. *J Cell Sci* 117(Pt 20): 4619–4628. PMID: [15371522](https://pubmed.ncbi.nlm.nih.gov/15371522/)
11. Chen P, Xie H, Sekar MC, Gupta K, Wells A. (1994) Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. *J Cell Biol* 127(3): 847–857. PMID: [7962064](https://pubmed.ncbi.nlm.nih.gov/7962064/)
12. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P. (1994) Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. *Nature* 372(6508): 786–791. PMID: [7997267](https://pubmed.ncbi.nlm.nih.gov/7997267/)
13. Zhu X, Assoian RK. (1995) Integrin-dependent activation of MAP kinase: a link to shape-dependent cell proliferation. *Mol Biol Cell* 6(3): 273–282. PMID: [7612963](https://pubmed.ncbi.nlm.nih.gov/7612963/)

14. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. *Breast Cancer Res Treat* 122(1): 35–43. doi: [10.1007/s10549-009-0502-2](https://doi.org/10.1007/s10549-009-0502-2) PMID: [19701706](https://pubmed.ncbi.nlm.nih.gov/19701706/)
15. Howe GA, Addison CL. (2012) beta1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy. *Cell Adh Migr* 6(2): 71–77. doi: [10.4161/cam.20077](https://doi.org/10.4161/cam.20077) PMID: [22568952](https://pubmed.ncbi.nlm.nih.gov/22568952/)
16. Morazzani M, de Carvalho DD, Kovacic H, Smida-Rezgui S, Briand C, Penel C. (2004) Monolayer versus aggregate balance in survival process for EGF-induced apoptosis in A431 carcinoma cells: Implication of ROS-P38 MAPK-integrin alpha2beta1 pathway. *Int J Cancer* 110(6): 788–799. PMID: [15170659](https://pubmed.ncbi.nlm.nih.gov/15170659/)
17. Pickl M, Ries CH. (2009) Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. *Oncogene* 28(3): 461–468. doi: [10.1038/onc.2008.394](https://doi.org/10.1038/onc.2008.394) PMID: [18978815](https://pubmed.ncbi.nlm.nih.gov/18978815/)
18. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, et al. (1998) Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. *Proc Natl Acad Sci U S A* 95(25): 14821–14826. PMID: [9843973](https://pubmed.ncbi.nlm.nih.gov/9843973/)
19. Windus LC, Kiss DL, Glover T, Avery VM. (2012) In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer. *Exp Cell Res* 318(19): 2507–2519. doi: [10.1016/j.yexcr.2012.07.013](https://doi.org/10.1016/j.yexcr.2012.07.013) PMID: [22841689](https://pubmed.ncbi.nlm.nih.gov/22841689/)
20. Josson S, Sharp S, Sung SY, Johnstone PA, Aneja R, Wang R, et al. (2010) Tumor-Stromal Interactions Influence Radiation Sensitivity in Epithelial- versus Mesenchymal-Like Prostate Cancer Cells. *J Oncol* 2010.
21. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, et al. (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. *Proc Natl Acad Sci U S A* 108(41): 17087–17092. doi: [10.1073/pnas.1108745108](https://doi.org/10.1073/pnas.1108745108) PMID: [21949389](https://pubmed.ncbi.nlm.nih.gov/21949389/)
22. Kim JK, Jung Y, Wang J, Joseph J, Mishra A, Hill EE, et al. (2013) TBK1 regulates prostate cancer dormancy through mTOR inhibition. *Neoplasia* 15(9): 1064–1074. PMID: [24027431](https://pubmed.ncbi.nlm.nih.gov/24027431/)
23. Taichman RS, Patel LR, Bedenis R, Wang J, Weidner S, Schumann T, et al. (2013) GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. *PLoS One* 8(4): e61873. doi: [10.1371/journal.pone.0061873](https://doi.org/10.1371/journal.pone.0061873) PMID: [23637920](https://pubmed.ncbi.nlm.nih.gov/23637920/)
24. Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, et al. (2013) Single cell transcriptomic analysis of prostate cancer cells. *BMC Mol Biol* 14: 6–16. doi: [10.1186/1471-2199-14-6](https://doi.org/10.1186/1471-2199-14-6) PMID: [23414343](https://pubmed.ncbi.nlm.nih.gov/23414343/)
25. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. *Cancer Res* 54(10): 2577–2581. PMID: [8168083](https://pubmed.ncbi.nlm.nih.gov/8168083/)
26. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. (2006) TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. *Cancer Res* 66(17): 8337–8341. PMID: [16951139](https://pubmed.ncbi.nlm.nih.gov/16951139/)
27. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, et al. (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. *PLoS One* 6(11): e27970. doi: [10.1371/journal.pone.0027970](https://doi.org/10.1371/journal.pone.0027970) PMID: [22114732](https://pubmed.ncbi.nlm.nih.gov/22114732/)
28. Nguyen HM, Corey E. (2011) Methodology to investigate androgen-sensitive and castration-resistant human prostate cancer xenografts in preclinical setting. *Methods Mol Biol* 776: 295–312. doi: [10.1007/978-1-61779-243-4_17](https://doi.org/10.1007/978-1-61779-243-4_17) PMID: [21796533](https://pubmed.ncbi.nlm.nih.gov/21796533/)
29. Ihnatovych I, Hu W, Martin JL, Fazleabas AT, de LP, Strakova Z. (2007) Increased phosphorylation of myosin light chain prevents in vitro decidualization. *Endocrinology* 148(7): 3176–3184. PMID: [17412815](https://pubmed.ncbi.nlm.nih.gov/17412815/)
30. Chery L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, et al. (2014) Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. *Oncotarget* 5(20): 9939–9951. PMID: [25301725](https://pubmed.ncbi.nlm.nih.gov/25301725/)
31. Tusher VG, Tibshirani R, Chu G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 98(9): 5116–5121. PMID: [11309499](https://pubmed.ncbi.nlm.nih.gov/11309499/)
32. Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM. (2013) Establishment and serial passage of cell cultures derived from LuCaP xenografts. *Prostate* 73(12): 1251–1262. doi: [10.1002/pros.22610](https://doi.org/10.1002/pros.22610) PMID: [23740600](https://pubmed.ncbi.nlm.nih.gov/23740600/)
33. Giancotti FG, Ruoslahti E. (1999) Integrin signaling. *Science* 285(5430): 1028–1032. PMID: [10446041](https://pubmed.ncbi.nlm.nih.gov/10446041/)
34. Gao J, Zhu Y, Nilsson M, Sundfeldt K. (2014) TGF-beta isoforms induce EMT independent migration of ovarian cancer cells. *Cancer Cell Int* 14(1): 72. doi: [10.1186/s12935-014-0072-1](https://doi.org/10.1186/s12935-014-0072-1) PMID: [25278811](https://pubmed.ncbi.nlm.nih.gov/25278811/)

35. Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, et al. (2015) NR2F1 controls tumor cell dormancy via SOX9 and RAR β driven quiescence programs. *Nat Commun.* 6: 6170–6184. doi: [10.1038/ncomms7170](https://doi.org/10.1038/ncomms7170) PMID: [25636082](https://pubmed.ncbi.nlm.nih.gov/25636082/)
36. Schiller HB, Hermann MR, Polleux J, Vignaud T, Zanivan S, Friedel CC, et al. (2013) beta1- and alphaV-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based micro-environments. *Nat Cell Biol* 15(6): 625–636. doi: [10.1038/ncb2747](https://doi.org/10.1038/ncb2747) PMID: [23708002](https://pubmed.ncbi.nlm.nih.gov/23708002/)
37. Sinpitaksakul SN, Pimkhaokham A, Sanchavanakit N, Pavasant P. (2008) TGF-beta1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway. *Biochem Biophys Res Commun* 371(4): 713–718. doi: [10.1016/j.bbrc.2008.04.128](https://doi.org/10.1016/j.bbrc.2008.04.128) PMID: [18457660](https://pubmed.ncbi.nlm.nih.gov/18457660/)
38. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, et al. (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. *Cancer Res* 68(15): 6241–6250. doi: [10.1158/0008-5472.CAN-07-6849](https://doi.org/10.1158/0008-5472.CAN-07-6849) PMID: [18676848](https://pubmed.ncbi.nlm.nih.gov/18676848/)
39. Aguirre Ghiso JA. (2002) Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. *Oncogene* 21(16): 2513–2524. PMID: [11971186](https://pubmed.ncbi.nlm.nih.gov/11971186/)
40. Street CA, Bryan BA. (2011) Rho kinase proteins—pleiotropic modulators of cell survival and apoptosis. *Anticancer Res* 31(11): 3645–3657. PMID: [22110183](https://pubmed.ncbi.nlm.nih.gov/22110183/)
41. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, et al. (2004) Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. *Cancer Cell* 6(2): 159–170. PMID: [15324699](https://pubmed.ncbi.nlm.nih.gov/15324699/)
42. Goodman SL, Picard M. (2012) Integrins as therapeutic targets. *Trends Pharmacol Sci* 33(7): 405–412. doi: [10.1016/j.tips.2012.04.002](https://doi.org/10.1016/j.tips.2012.04.002) PMID: [22633092](https://pubmed.ncbi.nlm.nih.gov/22633092/)
43. Zhao X, Guan JL. (2011) Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. *Adv Drug Deliv Rev* 63(8): 610–615. doi: [10.1016/j.addr.2010.11.001](https://doi.org/10.1016/j.addr.2010.11.001) PMID: [21118706](https://pubmed.ncbi.nlm.nih.gov/21118706/)
44. Keely PJ. (2011) Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. *J Mammary Gland Biol Neoplasia* 16(3): 205–219. doi: [10.1007/s10911-011-9226-0](https://doi.org/10.1007/s10911-011-9226-0) PMID: [21822945](https://pubmed.ncbi.nlm.nih.gov/21822945/)
45. Cox EA, Sastry SK, Huttenlocher A. (2001) Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases. *Mol Biol Cell* 12(2): 265–277. PMID: [11179414](https://pubmed.ncbi.nlm.nih.gov/11179414/)
46. Worthington JJ, Klementowicz JE, Travis MA. (2011) TGFbeta: a sleeping giant awoken by integrins. *Trends Biochem Sci* 36(1): 47–54. doi: [10.1016/j.tibs.2010.08.002](https://doi.org/10.1016/j.tibs.2010.08.002) PMID: [20870411](https://pubmed.ncbi.nlm.nih.gov/20870411/)
47. Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, et al. (2013) TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-R1II and p38alpha/beta signalling. *Nat Cell Biol* 15(11): 1351–1361. doi: [10.1038/ncb2861](https://doi.org/10.1038/ncb2861) PMID: [24161934](https://pubmed.ncbi.nlm.nih.gov/24161934/)
48. Peters G. (1994) The D-type cyclins and their role in tumorigenesis. *J Cell Sci Suppl* 18: 89–96. PMID: [7883799](https://pubmed.ncbi.nlm.nih.gov/7883799/)
49. Lim JT, Mansukhani M, Weinstein IB. (2005) Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. *Proc Natl Acad Sci U S A* 102(14): 5156–5161. PMID: [15790678](https://pubmed.ncbi.nlm.nih.gov/15790678/)
50. Chen CR, Kang Y, Siegel PM, Massague J (2002) E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. *Cell* 110(1): 19–32. PMID: [12150994](https://pubmed.ncbi.nlm.nih.gov/12150994/)
51. Yang J, Song K, Krebs TL, Jackson MW, Danielpour D (2008) Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression. *Oncogene* 27(40): 5326–5338. doi: [10.1038/onc.2008.165](https://doi.org/10.1038/onc.2008.165) PMID: [18504435](https://pubmed.ncbi.nlm.nih.gov/18504435/)
52. Song K, Wang H, Krebs TL, Wang B, Kelley TJ, Danielpour D (2010) DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. *Mol Endocrinol* 24(10): 2019–2029. doi: [10.1210/me.2010-0165](https://doi.org/10.1210/me.2010-0165) PMID: [20739403](https://pubmed.ncbi.nlm.nih.gov/20739403/)
53. Crosby ME, Jacobberger J, Gupta D, Macklis RM, Almasan A (2007) E2F4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma. *Oncogene* 26(13): 1897–1909. PMID: [17043659](https://pubmed.ncbi.nlm.nih.gov/17043659/)